Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, outlines therapeutic options for the treatment of patients with RET-positive lung cancer, highlighting the use of selpercatinib and pralsetinib in advanced disease. Dr Cappuzzo also discusses the importance of screening patients for RET rearrangements. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.